NicOx Reacquires Rights to Pfizer Glaucoma Drug

6 August 2009 (Last Updated August 6th, 2009 18:30)

NicOx has an agreement with Pfizer to reacquire the rights to PF-03187207, a promising new treatment for glaucoma and ocular hypertension. Under the terms of the new agreement, NicOx will reacquire full development and commercialisation rights (including the right to sublicense) to PF-031

NicOx has an agreement with Pfizer to reacquire the rights to PF-03187207, a promising new treatment for glaucoma and ocular hypertension.

Under the terms of the new agreement, NicOx will reacquire full development and commercialisation rights (including the right to sublicense) to PF-03187207, which has already completed Phase II testing, as well as the entire data package and development information.

In return, NicOx has agreed to pay Pfizer two undisclosed milestones (the first of which is linked to approval in the US, EU and Japan, and the second on reaching predefined sales levels), in addition to royalties on future sales.

NicOx will also regain the rights to a number of novel, research-stage, nitric oxide-donating compounds for the potential treatment of diabetic retinopathy and glaucoma.

NicOx can also access and use certain proprietary Xalatan® development information and cross-refer to Xalatan regulatory filings, which could be important for the potential future development and regulatory filing of PF¬03187207.

NicOx vice-president of business development Gavin Spencer said that the compound could represent an important new treatment option for the benefit of patients worldwide.

"We will evaluate opportunities for advancing PF-03187207 into Phase III, including possible third-party partnerships," Spencer said.

In the Phase II studies conducted in the US and Japan, the two highest doses of PF-03187207 showed an improvement over Xalatan 0.005% of up to 12%, in terms of the diurnal intraocular pressure (IOP) reduction at day 28, compared to baseline.